Skip to main content
. 2023 Jan 20;18:43. doi: 10.1186/s13019-023-02104-9

Table 1.

Preoperative cohort characteristics

Variable Smokers (n = 135) Non-smokers (n = 223) Ex-smokers (n = 183) p value
Median (1Q; 3Q) Median (1Q; 3Q) Median (1Q; 3Q)
Weight [kg] 82 (72; 94) 80 (71; 92) 85 (74; 96) 0.049
Heigth [cm] 174 (168; 178) 170 (161; 176) 172 (167; 175)  < 0.001
Age [years] 58.7 (52.9; 66.0) 69.2 (61.1; 76.2) 66.5 (58.8; 73.0)  < 0.0001
BMI [kg· m−2] 27.3 (24.6; 30.5) 27.9 (25.6; 31.2) 28.4 (25.8; 31.7) 0.05
BSA [m2] 1.96 (1.83; 2.12) 1.91 (1.79; 2.06) 1.98 (1.84; 2.11) 0.01
Creatinin [μmol/l] 84.0 (70; 97) 88.0 (75; 103) 87.0 (76; 105) 0.03
LVEF [%] 59 (45; 65) 60 (55; 65) 55 (45; 65)  < 0.001
EuroSCORE II [%] 0.98 (0.69; 1.75) 1.23 (0.82; 2.09) 1.14 (0.75; 2.51) 0.02
Variable Number Percentage Number Percentage Number Percentage p value
Female sex [n, %] 16 (11.9) 80 (35.9) 29 (15.9)  < 0.0001
Diabetes [n, %] 34 (25.2) 79 (35.4) 69 (37.7) 0.049
Hypertension [n, %] 99 (73.3) 186 (83.4) 139 (76.0) 0.05
Renal Failure [n, %] 5 (3.7) 8 (3.6) 8 (4.4) 0.91
Dyslipidemia [n, %] 77 (57.0) 148 (66.4) 126 (68.9) 0.08
Cardiac arrhythmias [n, %]: 0.66
Atrial Fibrillation/Flutter 6 (4.4) 15 (6.7) 11 (6.0)
Pacemaker 1 (0.7) 6 (2.7) 3 (1.6)
Cerebral ATS [n, %] 8 (5.9) 13 (5.8) 15 (8.2) 0.59
PAD [n, %] 27 (20.0) 15 (6.7) 35 (19.1)  < 0.001
COPD [n, %] 35 (25.9) 12 (5.4) 28 (15.3)  < 0.0001
Stroke [n, %] 10 (7.4) 18 (8.1) 22 (12.0) 0.27
CCS class [n, %]: 0.02
I 57 (42.5) 60 (27.0) 66 (36.1)
II 33 (24.6) 69 (31.1) 60 (32.8)
III 23 (17.2) 55 (24.8) 40 (21.9)
IV 21 (15.7) 38 (17.1) 17 (9.3)
NYHA class [n, %]: 0.09
I 72 (53.7) 85 (38.3) 75 (41.0)
II 46 (34.3) 87 (39.2) 77 (42.1)
III 12 (9.0) 40 (18.0) 25 (13.7)
IV 4 (3.0) 10 (4.5) 6 (3.3)
History of AMI [n, %] 77 (57.0) 95 (42.6) 111 (60.7)  < 0.001
Previous Cardiac Surgery [n, %] 11 (8.2) 21 (9.4) 11 (6.0) 0.45
Extent of Coronary Disease [n, %]: 0.1
1-vessel 70 (51.9) 115 (51.6) 73 (39.9)
2-vessel 43 (31.9) 67 (30.0) 64 (35.0)
3-vessel 22 (16.3) 41 (18.4) 46 (25.1)
Previous PCI [n, %] 43 (31.9) 56 (25.1) 72 (39.3) 0.009
Severe heart valve disease [n, %] 17 (12.6) 28 (12.6) 23 (12.6) 1
Intravenous nitrates preoperatively [n, %] 4 (3.0) 4 (1.8) 5 (2.7) 0.7
Anticoagulation preoperatively [n, %] 37 (27.4) 46 (20.6) 31 (16.9) 0.08

The influence of smoking status on the outcomes was tested by Pearson’s Chi-square test for categorical variables, and Kruskal–Wallis nonparametric analysis of variance with post-hoc Dunn ‘s test with Bonferroni modification for continuous variables

Values highlighted in bold were found to be statistically significant

1Q first quartile; 3Q third quartile; AMI acute myocardial infarction, BMI body mass index; BSA body surface area; CCS Canadian Cardiovascular Society classification of chest angina; Cerebral ATS cerebral atherosclerosis defined as a radiologically proven significant stenosis of cardinal cerebral vessels; COPD chronic obstructive pulmonary disease; EuroSCORE II risk model for the calculation of the risk of 30-day mortality after cardiac surgery; LVEF left ventricular ejection fraction; NYHA New York Heart Association classification of dyspnea; PAD peripheral artery disease; PCI percutaneous coronary intervention; Severe heart valve disease—defined as higher than moderate grade of any heart valve regurgitation/stenosis